Sensei Biotherapeutics Inc at Canaccord Genuity Growth Conference Transcript
Hey. Good morning, everybody, and thank you very much for joining us at the 43rd Annual Canaccord Genuity Growth Conference here in sunny Boston today. I'm John Newman and one of the biotech analysts here at the firm. We're very excited to have Sensei with us today. Joining us is the Chief Scientific Officer, Edward van der Horst. Welcome, Edward.
So wondering if you could start off talking about some of the key challenges for immuno-oncology in treating solid tumors, though it's kind of a broad question and also the approaches that Sensei brings to that challenge. Thanks.
Sure. Good morning, everybody. Yeah, this is -- there is the question is (technical difficulty) targeting solid tumors (technical difficulty) act for a second what (technical difficulty) its cancer and compared to other indications or disease areas. So if you compare that, say, cancer to cardiovascular, then abstract that a little bit. Cardiovascular
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |